|
The Medicare Drug Price Negotiation Program (MDPNP), a provision of the Inflation Reduction Act, requires Medicare to establish maximum fair prices (MFPs) for 10-15 drugs per year. This program will take effect on January 1, 2026. The basic impact of this program on pharmacies is that pharmacies will only be reimbursed by the Medicare Part D plan up to the MFP for these drugs and will be retrospectively reimbursed the difference between the pharmacy's acquisition cost and the MFP by the manufacturer.
Pharmacies choosing to stock these medications should be prepared to meet the requirements of the MDPNP, including enrolling in a Manufacturer Transaction Facilitator (MTF), which will enable the pharmacy to be reimbursed by the manufacturer for these drugs when they are dispensed.
Confused? We get it. That's why PSW created this webpage to provide pharmacies with the information they need to know about the MDPNP, including the drug lists, MFPs, reimbursement plans from manufacturers, how to enroll in an MTF, and more.
Click here to visit the PSW MDPNP guide for pharmacies.
|